Close Menu

Orig3n

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A number of experts have questioned the clinical validity underlying Interleukin's tests and hope Orig3n will not revive them.

Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.

The American Dental Association wants insurers and test manufacturers to show genetic testing is scientifically valid before they're used to determine coverage eligibility.

The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.

Geneticists and periodontists point to financial conflicts, the lack of genetics knowhow, and regulatory gaps for the availability of a test they say should have never come to market.

The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.

This week's news includes Alere, Fulget Diagnostics, Trovagene, Great Basic Scientific, Interleukin, and Danaher.

The private placement will include a syndicate of existing investors, as well as members of the company's senior management.

Pages

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.